However, while for the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) several meta-analyses of existing data have convincingly demonstrated that they do not cause any substantial change in overall [52], [53] or site-specific cancer risk [54]–[59], this is the first meta-analysis that focuses specifically on the relationship between fibrates and cancer. Here, HMGCR is linked to cancer.